News

March 02, 2018

Dr. Tranah will present at the California Academy of Sciences on March 15th, at 7:45pm.  "I Got Rhythm!" – How circadian rhythms coordinate the brain and body to impact human health and aging. For more information, please visit: http://wonderfest.org/brain-and-body-inquiry-mar-15/

 

March 02, 2018

The Osteoporotic Fractures in Men (MrOS) Study, a study of healthy aging with a focus on osteoporosis and fractures in 5,994 older men 65 years and older, has released over 16 years of prospective data on MrOS Online https://mrosdata.sfcc-cpmc.net/.

 

MrOS Online provides data, documentation, and study procedures from the multi-center MrOS Study.  With over 41,000 variables across seven time points, the MrOS Online database includes:

 

  • Assessment of falls, fractures, and mortality
  • Performance tests and lifestyle questionnaires
  • Objective and subjective measures of physical activity
  • Data from x-ray images, DXA, QCT, and HRpQCT scans
  • Objective and subjective sleep data from the MrOS Sleep ancillary study (n=3,135)
  • Tracking of cardiovascular events from the MrOS Sleep ancillary study
  • Oral health assessments from the MrOS Dental ancillary visit (n=1,353)
  • Biospecimen data, including serum chemistry, hormones, and cytokines

 

The online database is available to the public and anyone who registers and accepts the terms of an online data use agreement can download or explore study data. Please note that only a subset of datasets from the MrOS archives are currently available online. Additional datasets will be publicly released in the near future.

 

The NIA blog/announcement can be found here:

https://www.nia.nih.gov/research/blog/2017/11/release-mros-dataset-offers-new-opportunities-investigators

October 03, 2017

Clinical trials of new drugs for the prevention of fracture are extremely expensive and typically go on for at least 3 years. Investigators have tried for decades to find a new more efficient way of conducting these trials more efficiently. The Foundation for NIH project on Bone Quality at the SFCC has discovered that hip BMD is a good surrogate for hip fracture in clinical trials.

The project has compiled data from over 100,000 participants in over 40 clinical trials. They have pooled all of this data together to create the most powerful existing tool for studying ways to make clinical trials more efficient. The project compared changes in hip BMD during the course of these trials and the change in risk of hip fracture. The scientists discovered that every 1% improvement in hip BMD in the trials accurately predicted about a 5% decrease in the risk of hip fractures. This result was presented at a recent conference held by the FDA about new guidelines for clinical trials and has been submitted to FDA to consider revising their guidelines to accept BMD as a “surrogate” to allow clinical trials to use hip BMD as an endpoint for trials to approve drug therapies for prevention of fracture. This would be a revolutionary change in approval of new treatments for osteoporosis.

 

October 03, 2017

High levels of mitochondrial DNA (mtDNA) heteroplasmy, a mixture of normal and mutated mtDNA molecules in a cell, lead to inherited mitochondrial diseases with neurological, sensory, and movement impairments. We measured mtDNA heteroplasmy at twenty disease-causing sites for associations with neurosensory and mobility function among elderly participants from a community-based study of aging.

 

May 01, 2016

In a study from MrOS from the SF Coordinating Center and led by Dr. Doug Bauer, we found that high levels of thyroid hormone that were not known to the patient or physician, indicated a 2.5 to 3.6 times greater chance of becoming frail later in life. This is a treatable condition that might lead to wasting bone and muscle.


(See abstract Virginii VS, et al. Subclinical thyroid dysfunction and frailty among older men. J Clin Endocrinol Metab 2015;100:4524-32.)